NCT01082029

Brief Summary

The accumulation of fluid behind the ear drum without any acute inflammation is known as otitis media with effusion (OME). It is the most common cause of acquired hearing loss during childhood. Long-term complications of OME include linguistic, developmental, and social development delays due to hearing loss. The cause of OME is not known; however, low grade infection of the middle ear, poor function of the eustachian tube between the ear and the throat, and adenoid hypertrophy have all been suggested as possible etiologies. Recent detection of the stomach enzyme pepsin in middle ear fluid has led some to propose that OME is related to the reflux of stomach contents into the ear, via the eustachian tube. The purpose of the investigators study is to determine whether anti-reflux medication may have a positive impact by clearing the accumulation of fluid in the middle ear with the aim of preventing or reducing hearing loss in children diagnosed with OME. Empiric anti-reflux therapy with proton pump inhibitor (PPI) medication is safe, proven and cost-effective. It is used widely as a diagnostic and treatment strategy in the presence of the signs and symptoms of gastroesophageal reflux disease (GERD). The signs and symptoms of GERD include heartburn, recurrent vomiting or regurgitation, acid taste in mouth, throat irritation, voice problems, heartburn, difficult or painful swallowing, asthma and recurrent pneumonia. This pilot study will be a double-blinded, randomized, placebo-controlled trial that will compare resolution rates for OME in children treated with lansoprazole or placebo for three months. At the end of the study, those patients who have persistent middle ear effusions will be brought to the operating room and have the fluid aspirated and sent for analysis for pepsin.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Mar 2010

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

March 4, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 5, 2010

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

April 14, 2015

Status Verified

April 1, 2015

Enrollment Period

4.3 years

First QC Date

March 4, 2010

Last Update Submit

April 12, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Collect the required data for sample size calculation

    The purpose of this pilot study is to collect required data for a sample size calculation for a larger clinical trial and to determine recruitment rates.

    Following the recruitment of 100 patients (~1 year)

Secondary Outcomes (1)

  • Resolution of Otitis Media with Effusion

    At presentation and at 1 month, 2months and 3 months post initiation of treatment

Study Arms (2)

Lansoprazole

EXPERIMENTAL
Drug: Lansoprazole

Placebo

PLACEBO COMPARATOR
Drug: Placebo

Interventions

The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.

Also known as: Prevacid
Lansoprazole

Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)

Placebo

Eligibility Criteria

Age1 Year - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children between the ages of 1 and 17 years referred to the McMaster Otolaryngology Clinic.
  • Presence of bilateral OME for at least 3 months based on:
  • Clinical history: patient may present with decrease in hearing, aural fullness and/or ear pressure, balance problems, ear tugging/rubbing, they typically do not have otalgia or fever.
  • Pneumatic otoscopy: observations suggestive of OME include presence of a dull tympanic membrane with presence of non purulent effusion (serous or mucoid), presence of a level of effusion, decrease or non motility of the tympanic membrane, retraction of the tympanic membrane.
  • Tympanometry: type B or type C tympanogram with normal air volume of the external auditory canal.
  • Pure tone audiometry: conductive hearing loss that typically varies from slight to moderate.

You may not qualify if:

  • Presence of acute otitis media as determined by history and physical examination:
  • History of rapid acute onset of significant otalgia, decrease in hearing, fever, irritability.
  • Pneumatic otoscopy revealing purulent effusion, yellowness and/or redness with hypervascularity of the tympanic membrane, bulging of tympanic membrane with decrease of normal landmarks.
  • Presence of craniofacial abnormalities
  • Previous middle ear surgery (excluding myringotomy and tube)
  • Allergic reactions to lansoprazole, and any other adverse drug interactions to lansoprazole.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mcmaster University Medical Centre 3V1 Clinic

Hamilton, Ontario, L8N 3Z5, Canada

Location

Related Publications (27)

  • Bluestone CD, Beery QC, Andrus WS. Mechanics of the Eustachian tube as it influences susceptibility to and persistence of middle ear effusions in children. Ann Otol Rhinol Laryngol. 1974 Mar-Apr;83:Suppl 11:27-34. doi: 10.1177/0003489474083s1103. No abstract available.

    PMID: 4819098BACKGROUND
  • Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005 Feb;100(2):283-9. doi: 10.1111/j.1572-0241.2005.41210.x.

    PMID: 15667483BACKGROUND
  • Crapko M, Kerschner JE, Syring M, Johnston N. Role of extra-esophageal reflux in chronic otitis media with effusion. Laryngoscope. 2007 Aug;117(8):1419-23. doi: 10.1097/MLG.0b013e318064f177.

    PMID: 17585281BACKGROUND
  • Deal L, Gold BD, Gremse DA, Winter HS, Peters SB, Fraga PD, Mack ME, Gaylord SM, Tolia V, Fitzgerald JF. Age-specific questionnaires distinguish GERD symptom frequency and severity in infants and young children: development and initial validation. J Pediatr Gastroenterol Nutr. 2005 Aug;41(2):178-85. doi: 10.1097/01.mpg.0000172885.77795.0f.

    PMID: 16056096BACKGROUND
  • Fass R, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE, Fennerty MB. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med. 1999 Oct 11;159(18):2161-8. doi: 10.1001/archinte.159.18.2161.

    PMID: 10527293BACKGROUND
  • Fiellau-Nikolajsen M, Lous J, Vang Pedersen S, Schousboe HH. Tympanometry in three-year-old children. I. A regional prevalence study on the distribution of tympanometric results in a non-selected population of 3-year-old children. Scand Audiol. 1977;6(4):199-204. doi: 10.3109/01050397709043121.

    PMID: 609889BACKGROUND
  • Fiellau-Nikolajsen M, Lous J. Prospective tympanometry in 3-year-old children. A study of the spontaneous course of tympanometry types in a nonselected population. Arch Otolaryngol. 1979 Aug;105(8):461-6. doi: 10.1001/archotol.1979.00790200023005.

    PMID: 464883BACKGROUND
  • Fiellau-Nikolajsen M. Tympanometry and secretory otitis media. Observations on diagnosis, epidemiology, treatment, and prevention in prospective cohort studies of three-year-old children. Acta Otolaryngol Suppl. 1983;394:1-73. No abstract available.

    PMID: 6314732BACKGROUND
  • Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol. 2000 Feb;95(2):395-407. doi: 10.1111/j.1572-0241.2000.01759.x.

    PMID: 10685741BACKGROUND
  • Golz A, Netzer A, Angel-Yeger B, Westerman ST, Gilbert LM, Joachims HZ. Effects of middle ear effusion on the vestibular system in children. Otolaryngol Head Neck Surg. 1998 Dec;119(6):695-9. doi: 10.1016/S0194-5998(98)70039-7.

    PMID: 9852553BACKGROUND
  • Grace AR, Pfleiderer AG. Dysequilibrium and otitis media with effusion: what is the association? J Laryngol Otol. 1990 Sep;104(9):682-4. doi: 10.1017/s0022215100113611.

    PMID: 2230572BACKGROUND
  • Heavner SB, Hardy SM, White DR, Prazma J, Pillsbury HC 3rd. Transient inflammation and dysfunction of the eustachian tube secondary to multiple exposures of simulated gastroesophageal refluxant. Ann Otol Rhinol Laryngol. 2001 Oct;110(10):928-34. doi: 10.1177/000348940111001007.

    PMID: 11642425BACKGROUND
  • Hicks DM, Ours TM, Abelson TI, Vaezi MF, Richter JE. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice. 2002 Dec;16(4):564-79. doi: 10.1016/s0892-1997(02)00132-7.

    PMID: 12512644BACKGROUND
  • Jonaitis L, Pribuisiene R, Kupcinskas L, Uloza V. Laryngeal examination is superior to endoscopy in the diagnosis of the laryngopharyngeal form of gastroesophageal reflux disease. Scand J Gastroenterol. 2006 Feb;41(2):131-7. doi: 10.1080/00365520600577940.

    PMID: 16484116BACKGROUND
  • Keles B, Ozturk K, Gunel E, Arbag H, Ozer B. Pharyngeal reflux in children with chronic otitis media with effusion. Acta Otolaryngol. 2004 Dec;124(10):1178-81. doi: 10.1080/00016480410017134.

    PMID: 15768814BACKGROUND
  • Lieu JE, Muthappan PG, Uppaluri R. Association of reflux with otitis media in children. Otolaryngol Head Neck Surg. 2005 Sep;133(3):357-61. doi: 10.1016/j.otohns.2005.05.654.

    PMID: 16143181BACKGROUND
  • Lous J, Fiellau-Nikolajsen M. Epidemiology and middle ear effusion and tubal dysfunction. A one-year prospective study comprising monthly tympanometry in 387 non-selected 7-year-old children. Int J Pediatr Otorhinolaryngol. 1981 Dec;3(4):303-17. doi: 10.1016/0165-5876(81)90055-0.

    PMID: 6976949BACKGROUND
  • Lous J. Secretory otitis media in schoolchildren. Is screening for secretory otitis media advisable? Dan Med Bull. 1995 Feb;42(1):71-99. No abstract available.

    PMID: 7729171BACKGROUND
  • Rodriguez-Tellez M. Supra-oesophageal manifestations of gastro-oesophageal reflux disease. Drugs. 2005;65 Suppl 1:67-73. doi: 10.2165/00003495-200565001-00010.

    PMID: 16335860BACKGROUND
  • Rozmanic V, Velepic M, Ahel V, Bonifacic D, Velepic M. Prolonged esophageal pH monitoring in the evaluation of gastroesophageal reflux in children with chronic tubotympanal disorders. J Pediatr Gastroenterol Nutr. 2002 Mar;34(3):278-80. doi: 10.1097/00005176-200203000-00009.

    PMID: 11964951BACKGROUND
  • Shekelle P, Takata G, et al. Diagnosis, Natural History, and Late Effects of Otitis Media with Effusion. Evidence Report/Technology Assessment No. 55 (Prepared by Southern California Evidence-based Practice Center under Contract No 290-97-0001, Task Order No. 4). AHRQ Publication No. 03-E023. Rockville, MD: Agency for Healthcare Research and Quality May 2003.

    BACKGROUND
  • Tasker A, Dettmar PW, Panetti M, Koufman JA, P Birchall J, Pearson JP. Is gastric reflux a cause of otitis media with effusion in children? Laryngoscope. 2002 Nov;112(11):1930-4. doi: 10.1097/00005537-200211000-00004.

    PMID: 12439157BACKGROUND
  • Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis. 1989 Jul;160(1):83-94. doi: 10.1093/infdis/160.1.83.

    PMID: 2732519BACKGROUND
  • White DR, Heavner SB, Hardy SM, Prazma J. Gastroesophageal reflux and eustachian tube dysfunction in an animal model. Laryngoscope. 2002 Jun;112(6):955-61. doi: 10.1097/00005537-200206000-00004.

    PMID: 12160291BACKGROUND
  • Vaezi MF. Therapy Insight: gastroesophageal reflux disease and laryngopharyngeal reflux. Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):595-603. doi: 10.1038/ncpgasthep0358.

    PMID: 16327839BACKGROUND
  • Velepic MM, Velepic MS, Starcevic R, Manestar D, Rozmanic V. Gastroesophageal reflux and sequelae of chronic tubotympanal disorders in children. Acta Otolaryngol. 2004 Oct;124(8):914-7. doi: 10.1080/00016480410022499.

    PMID: 15513526BACKGROUND
  • Al-Saab F, Manoukian JJ, Al-Sabah B, Almot S, Nguyen LH, Tewfik TL, Daniel SJ, Schloss MD, Hamid QA. Linking laryngopharyngeal reflux to otitis media with effusion: pepsinogen study of adenoid tissue and middle ear fluid. J Otolaryngol Head Neck Surg. 2008 Aug;37(4):565-71.

    PMID: 19128594BACKGROUND

MeSH Terms

Conditions

Otitis Media with Effusion

Interventions

Lansoprazole

Condition Hierarchy (Ancestors)

Otitis MediaOtitisEar DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

2-PyridinylmethylsulfinylbenzimidazolesSulfoxidesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Dr. Diane Reid, MD FRCSC

    McMaster University

    PRINCIPAL INVESTIGATOR
  • Dr. Gavin Rukholm, MD

    McMaster University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr Gavin Rukholm, MD FRCSC

Study Record Dates

First Submitted

March 4, 2010

First Posted

March 5, 2010

Study Start

March 1, 2010

Primary Completion

June 1, 2014

Study Completion

June 1, 2014

Last Updated

April 14, 2015

Record last verified: 2015-04

Locations